Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 21, 2009
Grant Date -
Dec 21, 2006
app pub date -
Apr 26, 2005
filing date -
Apr 26, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the proteolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully